Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.
Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.
The manifesto is built on three “separate but highly interdependent pillars”:
1. Improve health outcomes & remove inequalities to better patient benefits;
2. Support sustainable & predictable healthcare systems to speed access to medicines;
3. Build a thriving innovative life sciences sector to promote European competitiveness.
It follows the launch of EFPIA’s #HealthyEU Health and Growth campaign, which outlines opportunities and threats faced by the patients and the healthcare sector.
EFPIA President, Sanofi CEO Christopher Viehbacher, highlighted how the technological, behavioural and therapeutic innovations outlined in the Manifesto should be used to rebuild sustainable healthcare systems, improve access to medicines and “do a better job at preventing and treating chronic disease”.
The research-based pharmaceutical industry employs over 700,000 people in Europe, and contributes 17% of total business enterprise R&D employment.
To view the EFPIA Maifesto, click here.
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
FDA Approves Stelara Biosimilar Selarsdi to Treat Psoriasis, Psoriatic Arthritis
April 17th 2024Alvotech’s and Teva's Selarsdi (ustekinumab-aekn), the second FDA-approved biosimilar to Stelara, is indicated to treat patients aged 6 years and above with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for patients aged 6 years and above with active psoriatic arthritis.